

NEWS RELEASE



Announcement Concerning Signing of Commitment Line Agreement

Tokyo, Japan, June 13th, 2018 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced that at the board meeting held today, Solasia has decided to enter into a commitment line agreement* (hereinafter “this agreement”) with Sumitomo Mitsui Banking Corporation. Details are shown as follows.

1. Purpose of this agreement

In May 2018, Solasia has launched episil® oral liquid (SP-03) in Japan, and is awaiting approval for SP-01 and SP-03 in China with all necessary clinical trials completed. There is additional capital required to carry out business activities to support these products. Furthermore, we are currently undergoing multinational Phase II clinical study for SP-02, and plan to initiate global Phase III clinical study for SP-04 in 2H 2018 as announced in a separate release today.

Solasia has been focusing on above business activities by utilizing JPY 2,772 million in cash and cash equivalents (as of March 31, 2018) and JPY 2,600 million in the overdraft facilities which were signed in November 2017. In addition, Solasia have decided to sign a commitment line agreement with Sumitomo Mitsui Banking Corporation for a loan capacity of JPY 1,000 million without collateral, to ensure further diversification and enhancement of financial resources.

(Note) Definition of commitment line :

A commitment line is an agreement where a financial institution promises (commits) to grant loans to a company upon request at any time, provided it is within the period and loan limit as pre-determined by both the financial institution and the company.

2. Summary of the terms of this agreement

Contracting party :	Sumitomo Mitsui Banking Corporation
Loan limit :	JPY 1,000 million
Contract date :	15 June 2018
Maturity date :	30 December 2019
Collateral :	None

3. Impact on financial forecast

The impact of executing this agreement is immaterial to the current fiscal year’s financial forecast.

NEWS RELEASE

Solasia

About Solasia:

Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers.

Additional information is available at <http://www.solasia.co.jp/en/>

(Contact)

Solasia Pharma K.K.

Rie Toyoda

Investor Relations

+81-3-5843-8049

info@solasia.co.jp